Viewpoint
  • About
    • Overview
    • Awards
    • Management Team
    • Board of Directors
    • Scientific Advisors
    • Partners
    • Pb-203 User Group
  • Technology
    • Theranostics
    • 𝛼-Particle Radiotherapy
    • VMT-𝛼-GEN
    • Publications
  • Pipeline
    • Overview
    • VMT01
    • VMT-𝛼-NET
  • News
    • Press Releases
    • Events
    • Email Alerts
  • Contact
Select Page

Viewpoint Molecular Targeting Announces Transformational Merger

by Barry | Sep 29, 2022 | Press Releases

CORALVILLE, IA / September 29, 2022 / Viewpoint Molecular Targeting, Inc. (“Viewpoint” or the “Company”), a radiopharmaceutical company developing precision lead-212-based α-particle oncology therapeutics and complementary diagnostic...

Viewpoint Molecular Targeting® to Present at the B. Riley Radiation Oncology Investor Day

by Barry | Feb 22, 2022 | Press Releases

Fireside chat with newly appointed CEO, Thijs Spoor, today, February 22 at 1:30 PM ETCORALVILLE, IA / February 22, 2022 / Viewpoint Molecular Targeting, Inc. (“Viewpoint” or the “Company”), a precision oncology company developing alpha-particle...

Viewpoint Molecular Targeting® Appoints Thijs Spoor as Chief Executive Officer

by Barry | Feb 22, 2022 | Press Releases

Established leader with nearly 30 years of combined executive, broad management and capital markets expertise across healthcare and medical device industriesCORALVILLE, IA / February 22, 2022 / Viewpoint Molecular Targeting, Inc. (“Viewpoint” or the...

Viewpoint Molecular Targeting® to Present at the Virtual Investor 2022 Top Picks Conference

by Barry | Jan 20, 2022 | Press Releases

– Live video webcast presentation on Tuesday, January 25th at 11:00 AM ETCORALVILLE, IA / January 20, 2022 / Viewpoint Molecular Targeting, Inc. (“Viewpoint” or the “Company”), a radiopharmaceutical company developing precision...

Viewpoint Molecular Targeting® to Present at the H.C. Wainwright BioConnect Conference

by Barry | Jan 5, 2022 | Press Releases

CORALVILLE, IA / January 5, 2022 / Viewpoint Molecular Targeting, Inc. (“Viewpoint” or the “Company”), a radiopharmaceutical company developing precision lead-212-based α-particle oncology therapeutics and complementary diagnostic imaging...
« Older Entries

Recent Posts

  • Viewpoint Molecular Targeting Announces Transformational Merger
  • Viewpoint Molecular Targeting® to Present at the B. Riley Radiation Oncology Investor Day
  • Viewpoint Molecular Targeting® Appoints Thijs Spoor as Chief Executive Officer
  • Viewpoint Molecular Targeting® to Present at the Virtual Investor 2022 Top Picks Conference
  • Viewpoint Molecular Targeting® to Present at the H.C. Wainwright BioConnect Conference

Recent Comments

    © 2022 Viewpoint Molecular Targeting®
    • Privacy Policy
    • Terms and Conditions
    • News
    • Contact
    • Follow
    • Follow
    We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept All”, you consent to the use of ALL the cookies. However, you may visit "Cookie Settings" to provide a controlled consent.
    Cookie SettingsAccept All
    Manage consent

    Privacy Overview

    This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
    Necessary
    Always Enabled
    Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
    CookieDurationDescription
    cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
    cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
    cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
    cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
    cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
    viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
    Functional
    Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
    Performance
    Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
    Analytics
    Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
    SAVE & ACCEPT